Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR11296765

—

2bf1226e-ac31-571b-ab19-ac40ab586f01

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.690
  • MYC_TARGETS_V1+0.660
  • E2F_TARGETS+0.600
  • INTERFERON_ALPHA_RESPONSE+0.570
  • OXIDATIVE_PHOSPHORYLATION+0.560
  • G2M_CHECKPOINT+0.510
  • MTORC1_SIGNALING+0.490
  • INTERFERON_GAMMA_RESPONSE+0.480
  • UNFOLDED_PROTEIN_RESPONSE+0.440
  • DNA_REPAIR+0.370

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.430
  • HEDGEHOG_SIGNALING-0.410
  • UV_RESPONSE_DN-0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
  • WNT_BETA_CATENIN_SIGNALING-0.300
  • NOTCH_SIGNALING-0.270
  • TNFA_SIGNALING_VIA_NFKB-0.270
  • MYOGENESIS-0.240
  • HYPOXIA-0.230
  • HEME_METABOLISM-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2278852
head-neck@1
——0.910
2SRR6013558
lung-landscapes@6
—cohortA40.905
3SRR6013495
lung-landscapes@6
—cohortA10.894
4MNG358
mng-umap@100
——0.889
5ddd65fce-1a39-415c-9114-7a9c8e9b266c
colon-landscapes@1
——0.883
6SRR8518360
breast-umap@18
—E0.880
7SRR17866821
colon-landscapes@1
——0.878
8992ce1bc-46a2-4f57-ac7a-c6368c69c67c
colon-landscapes@1
——0.873
9TCGA-A8-A06X-01A-21R-A00Z-07
breast-umap@18
—B0.867
10TCGA-D8-A1Y3-01A-11R-A157-07
breast-umap@18
—B0.865

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.690Idelalisib— uncovered
MYC_TARGETS_V10.660Inavolisib— uncovered
E2F_TARGETS0.600Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.570Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.560Remibrutinib— uncovered
G2M_CHECKPOINT0.510Inavolisib— uncovered
MTORC1_SIGNALING0.490Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.480Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.440Idelalisib— uncovered
DNA_REPAIR0.370Idelalisib— uncovered
FATTY_ACID_METABOLISM0.340Inavolisib— uncovered
GLYCOLYSIS0.310Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.310Inavolisib— uncovered
ADIPOGENESIS0.290Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.290Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.270Idelalisib— uncovered
PEROXISOME0.200Idelalisib— uncovered
P53_PATHWAY0.140Idelalisib— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.110Idelalisib— uncovered